文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

AGO关于局部晚期和转移性乳腺癌患者诊断与治疗的建议：2022年更新版

AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022.

作者信息

Thill Marc, Lüftner Diana, Kolberg-Liedtke Cornelia, Albert Ute-Susann, Banys-Paluchowski Maggie, Bauerfeind Ingo, Blohmer Jens-Uwe, Budach Wilfried, Dall Peter, Fallenberg Eva Maria, Fasching Peter A, Fehm Tanja, Friedrich Michael, Gerber Bernd, Gluz Oleg, Harbeck Nadia, Heil Jörg, Huober Jens, Jackisch Christian, Kreipe Hans-Heinrich, Krug David, Kühn Thorsten, Kümmel Sherko, Loibl Sibylle, Lux Michael, Maass Nicolai, Mundhenke Christoph, Nitz Ulrike, Park-Simon Tjoung-Won, Reimer Toralf, Rhiem Kerstin, Rody Achim, Schmidt Marcus, Schneeweiss Andreas, Schütz Florian, Sinn Hans-Peter, Solbach Christine, Solomayer Erich-Franz, Stickeler Elmar, Thomssen Christoph, Untch Michael, Witzel Isabell, Wöckel Achim, Müller Volkmar, Janni Wolfgang, Ditsch Nina

机构信息

Klinik für Gynäkologie und Gynäkologische Onkologie, Agaplesion Markus Krankenhaus, Frankfurt, Germany.

Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie, Charité, Berlin, Germany.

出版信息

Breast Care (Basel). 2022 Aug;17(4):421-429. doi: 10.1159/000524789. Epub 2022 May 2.

DOI:10.1159/000524789
PMID:36156913
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9453659/
Abstract

The Breast Committee of the Arbeitsgemeinschaft Gynäkologische Onkologie (German Gynecological Oncology Group, AGO) presents the 2022 update of the evidence-based recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer.

摘要

德国妇科肿瘤学会（AGO）乳腺委员会发布了2022年局部晚期和转移性乳腺癌患者诊断与治疗的循证建议更新版。

相似文献

[1]
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022.

Breast Care (Basel). 2022-8

[2]
Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2024.

Breast Care (Basel). 2024-6

[3]
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2023.

Breast Care (Basel). 2023-8

[4]
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019.

Breast Care (Basel). 2019-8

[5]
Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2024.

Breast Care (Basel). 2024-6

[6]
Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2023.

Breast Care (Basel). 2023-8

[7]
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022.

Breast Care (Basel). 2022-8

[8]
ABC7 Consensus: Assessment by a German Group of Experts.

Breast Care (Basel). 2024-4

[9]
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2018.

Breast Care (Basel). 2018-7

[10]
International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus - Assessment by a German Group of Experts.

Breast Care (Basel). 2020-2

引用本文的文献

[1]
Oncological outcomes of breast cancer patients after planned IORT boost with low-kV x-rays-results of the TARGIT BQR prospective phase IV trial.

Strahlenther Onkol. 2025-5-19

[2]
Thymidine kinase 1 concentration and activity in metastatic breast cancer under CDK4/6 inhibitor therapy.

Sci Rep. 2025-3-25

[3]
Prognostic Factors in Therapy Regimes of Breast Cancer Patients with Brain Metastases: A Retrospective Monocentric Analysis.

Cancers (Basel). 2025-1-15

[4]
Attrition between lines of therapy and real-world outcomes of patients with HER2-positive metastatic breast cancer in Europe: a cohort study leveraging electronic medical records.

Breast Cancer Res Treat. 2025-1

[5]
Acute and Long-Term Toxicity after Planned Intraoperative Boost and Whole Breast Irradiation in High-Risk Patients with Breast Cancer-Results from the Targeted Intraoperative Radiotherapy Boost Quality Registry (TARGIT BQR).

Cancers (Basel). 2024-5-30

[6]
heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer.

BMC Cancer. 2024-5-24

[7]
Metastatic Breast Cancer: Prolonging Life in Routine Oncology Care.

Cancers (Basel). 2024-3-22

[8]
Successful management of bilateral orbital metastases from invasive lobular breast cancer with abemaciclib and letrozole: a case report and literature review.

Front Oncol. 2024-1-23

[9]
Ratios of monocytes and neutrophils to lymphocytes in the blood predict benefit of CDK4/6 inhibitor treatment in metastatic breast cancer.

Sci Rep. 2023-12-2

[10]
Narrative Review of Multidisciplinary Management of Central Nervous Involvement in Patients with HER2-Positive Metastatic Breast Cancer: Focus on Elderly Patients.

Adv Ther. 2023-8

本文引用的文献

[1]
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.

N Engl J Med. 2022-3-24

[2]
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.

N Engl J Med. 2022-3-10

[3]
Primary Surgery with Systemic Therapy in Patients with de Novo Stage IV Breast Cancer: 10-year Follow-up; Protocol MF07-01 Randomized Clinical Trial.

J Am Coll Surg. 2021-12

[4]
Pathogenic DPYD Variants and Treatment-Related Mortality in Patients Receiving Fluoropyrimidine Chemotherapy: A Systematic Review and Meta-Analysis.

Oncologist. 2021-12

[5]
EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours.

Ann Oncol. 2021-11

[6]
Contralateral Axillary Nodal Metastases: Stage IV Disease or a Manifestation of Progressive Locally Advanced Breast Cancer?

Ann Surg Oncol. 2021-10

[7]
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.

Ann Oncol. 2021-8

[8]
PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer.

Cochrane Database Syst Rev. 2021-4-22

[9]
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.

N Engl J Med. 2021-4-22

[10]
The Effect of Primary Surgery in Patients with De Novo Stage IV Breast Cancer with Bone Metastasis Only (Protocol BOMET MF 14-01): A Multi-Center, Prospective Registry Study.

Ann Surg Oncol. 2021-9

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索